Denali Therapeutics (NASDAQ:DNLI) Price Target Cut to $30.00

Denali Therapeutics (NASDAQ:DNLI) had its price target decreased by Wedbush from $31.00 to $30.00 in a research note issued to investors on Wednesday, Benzinga reports. The firm presently has an “outperform” rating on the stock. Wedbush’s target price indicates a potential upside of 56.66% from the company’s current price.

Other equities analysts also recently issued research reports about the stock. The Goldman Sachs Group cut their price objective on shares of Denali Therapeutics from $73.00 to $50.00 and set a “buy” rating on the stock in a report on Thursday, February 29th. HC Wainwright reissued a “buy” rating and issued a $95.00 target price on shares of Denali Therapeutics in a research report on Wednesday. UBS Group reduced their price objective on Denali Therapeutics from $70.00 to $32.00 and set a “buy” rating for the company in a research note on Tuesday, April 9th. Finally, Stifel Nicolaus cut their price target on shares of Denali Therapeutics from $26.00 to $22.00 and set a “hold” rating on the stock in a report on Wednesday. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $40.22.

Denali Therapeutics Trading Up 13.6 %

Shares of Denali Therapeutics stock traded up $2.30 during trading on Wednesday, hitting $19.15. 880,093 shares of the stock traded hands, compared to its average volume of 1,158,718. The stock’s fifty day simple moving average is $18.82 and its 200 day simple moving average is $18.84. The firm has a market cap of $2.73 billion, a P/E ratio of -17.64 and a beta of 1.39. Denali Therapeutics has a 52-week low of $14.56 and a 52-week high of $33.31.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings data on Tuesday, May 7th. The company reported ($0.68) EPS for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.01. Denali Therapeutics had a negative net margin of 36.51% and a negative return on equity of 13.50%. During the same period in the prior year, the business earned ($0.80) earnings per share. As a group, equities analysts expect that Denali Therapeutics will post -2.61 EPS for the current year.

Insider Transactions at Denali Therapeutics

In other Denali Therapeutics news, Director Vicki L. Sato sold 1,666 shares of the firm’s stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $18.29, for a total value of $30,471.14. Following the sale, the director now directly owns 118,043 shares of the company’s stock, valued at $2,159,006.47. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, Director Vicki L. Sato sold 1,666 shares of the firm’s stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $18.29, for a total value of $30,471.14. Following the transaction, the director now owns 118,043 shares in the company, valued at $2,159,006.47. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Carole Ho sold 2,784 shares of the company’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $17.29, for a total transaction of $48,135.36. Following the sale, the insider now directly owns 145,010 shares of the company’s stock, valued at approximately $2,507,222.90. The disclosure for this sale can be found here. Insiders have sold a total of 110,955 shares of company stock valued at $2,218,802 in the last ninety days. 7.90% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. CWM LLC increased its position in shares of Denali Therapeutics by 216.7% during the 4th quarter. CWM LLC now owns 2,011 shares of the company’s stock worth $43,000 after purchasing an additional 1,376 shares during the last quarter. Assetmark Inc. increased its position in shares of Denali Therapeutics by 49.1% during the third quarter. Assetmark Inc. now owns 2,148 shares of the company’s stock valued at $44,000 after acquiring an additional 707 shares during the last quarter. PNC Financial Services Group Inc. lifted its holdings in shares of Denali Therapeutics by 48.1% in the 4th quarter. PNC Financial Services Group Inc. now owns 2,486 shares of the company’s stock worth $53,000 after acquiring an additional 807 shares during the last quarter. Fisher Asset Management LLC purchased a new position in shares of Denali Therapeutics during the 4th quarter worth approximately $59,000. Finally, China Universal Asset Management Co. Ltd. increased its holdings in Denali Therapeutics by 96.5% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,526 shares of the company’s stock valued at $73,000 after purchasing an additional 1,732 shares during the last quarter. 92.92% of the stock is currently owned by hedge funds and other institutional investors.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.